Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
European Journal of Epidemiology|November 5, 1997
Enterotoxin and toxic shock syndrome toxin-1 production of methicillin resistant and methicillin sensitive Staphylococcus aureus strainsF J Schmitz, C R MacKenzie, R Geisel, et al.
Intensive Care Medicine|March 1, 1997
Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltrationP Heering, S Morgera, F J Schmitz, et al.
The Journal of Antimicrobial Chemotherapy|March 17, 2001
The prevalence of aminoglycoside resistance and corresponding resistance genes in clinical isolates of staphylococci from 19 European hospitalsF J Schmitz, A C Fluit, M Gondolf, et al.
Antimicrobial Agents and Chemotherapy|February 22, 2001
In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureusM Boos, S Mayer, A Fischer, et al.
Antimicrobial Agents and Chemotherapy|October 3, 1999
Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolonesS Brisse, A C Fluit, U Wagner, et al.
The Journal of Antimicrobial Chemotherapy|March 3, 1999
The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureusF J Schmitz, A C Fluit, M Lückefahr, et al.
Antimicrobial Agents and Chemotherapy|October 19, 2000
Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolatesF J Schmitz, A C Fluit, D Hafner, et al.
Urology|July 22, 1999
Abuse of guaifenesin-containing medications generates an excess of a carboxylate salt of beta-(2-methoxyphenoxy)-lactic acid, a guaifenesin metabolite, and results in urolithiasisC L Pickens, A R Milliron, A L Fussner, et al.
The Journal of Antimicrobial Chemotherapy|May 23, 1998
Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureusF J Schmitz, B Hofmann, B Hansen, et al.
Lancet (London, England)|June 27, 2001
In-vivo transfer of mecA DNA to Staphylococcus aureus [corrected]C L Wielders, M R Vriens, S Brisse, et al.
Pageof 14